How profitable is COMPASS Pathways Plc American Depository Shares (CMPS)?

In FY 2025 (10-K), CMPS converted $501.3M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / CMPS / financials

URGN (24) MLYS (33) NBTX (49) RARE (23) ⌘ Pro Terminal →

COMPASS Pathways Plc American Depository Shares (CMPS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.41 -27.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.98

COMPASS Pathways Plc American Depository Shares (CMPS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.60B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CMPS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CMPS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, COMPASS Pathways Plc American Depository Shares (NASDAQ: CMPS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $8.41 (-27.31% 1D, market cap $1.60B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CMPS ranks #456 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CMPS compare to URGN and MLYS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMPS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, URGN (UroGen Pharma Ltd.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and MLYS (Mineralys Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.4%, cap $1.61B). Among the 5-stock peer group, CMPS leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CMPS?

▼

Per CMPS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001816590), COMPASS Pathways Plc American Depository Shares generated $501.3M in revenue (+0.5% YoY), -$269.8M in net income, and -$157.2M in free cash flow against $210.3M in total assets and $14.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.98 (-5.11%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CMPS)Realized 20D OHLCV Swing Band: ±10.6%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY CMPS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)

FRED Regime × Technicals: 32% of 52W Range • RSI-14 at 46.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.14+6.8% Next Q

Q2 (-2Q)

Grade D$11.90-0.8% Next Q

Q3 (-1Q)

Grade D$11.81-28.8% Next Q

Current

Grade D-$8.41-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CMPS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CMPS currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.83) and Max Pain ($8.83) forces dealer call-delta covering toward $16.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CMPS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CMPS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CMPS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $383.4M

FY24

Rev $499.0M

FY25

Rev $501.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$501.3M	52%	-35.7%	-$269.8M	-$157.2M	-45%
FY 2024	$499.0M	52%	-35.7%	-$155.1M	-$119.2M	-45%
FY 2023	$383.4M	52%	-35.7%	-$118.5M	-$97.4M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CMPS)

✓Walkthrough of CMPS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CMPS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.66%▼ SUPPORT BREAKDOWN

2026-11-03O $12.19H $12.19L $8.41C $8.41VOL 2.18M

RES: $16.24SUP: $10.30SMA50: $12.83SMA200: $10.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CMPS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CMPS Butterfly Map → + Track CMPS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CMPS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CMPS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CMPS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CMPS)

Health Care Rank #456 of 1015 ⚔️ URGN vs CMPS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CMPS vs. URGN, MLYS, NBTX, RARE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, COMPASS Pathways Plc American Depository Shares (CMPS) ranks #456 by composite RQD confidence (40/100, grade D-) and #290 by equity capitalization ($1.60B). Within this direct 5-issuer industry benchmark cohort, CMPS leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. NBTX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with CMPS at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CMPS ACTIVE COMPASS Pathways Plc American Depository Shares	D-	40/100	—	—	-35.0%	-27.31%	$1.60B	Benchmark Subject
URGN UroGen Pharma Ltd.	E	24/100	—	88.7%	-35.0%	+5.01%	$1.60B	/urgn-vs-cmps →
MLYS Mineralys Therapeutics Inc.	E	33/100	—	—	-28.4%	-14.47%	$1.61B	/mlys-vs-cmps →
NBTX Nanobiotix S.A.	D	49/100	—	—	—	-10.39%	$1.59B	/nbtx-vs-cmps →
RARE Ultragenyx Pharmaceutical Inc.	E	23/100	—	—	-35.0%	+1.24%	$1.59B	/rare-vs-cmps →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001816590 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), COMPASS Pathways Plc American Depository Shares (CMPS) reported GAAP revenue of $501.3M (+0.5% vs. FY2024 revenue of $499.0M , and +30.8% cumulative change since FY2023) , GAAP net income of -$269.8M, operating cash flow of -$157.2M, and free cash flow of -$157.2M (-31.9% YoY). On the balance sheet, CMPS closed FY2025 with $210.3M in total assets against $14.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$501.3M	-$269.8M	-$157.2M	-$157.2M	$210.3M	$14.1M
FY2024 (FY)	2024-12-31	$499.0M	-$155.1M	-$119.2M	-$119.2M	$213.7M	$24.7M
FY2023 (FY)	2023-12-31	$383.4M	-$118.5M	-$97.4M	-$97.4M	—	—

3. CMPS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CMPS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CMPS compare to URGN and MLYS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CMPS?

Where is CMPS trading relative to its 50-day, 200-day, and 52-week technical levels?

CMPS last traded at $8.41 (-27.31% on volume of 16,850,617 shares), positioning the stock -34.45% below its 50-day simple moving average ($12.83) and -19.52% below its 200-day simple moving average ($10.45). Across its 52-week range of $4.88 to $15.87, CMPS sits at the 32.1% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($7.52 to $9.30).

Direct Sub-Reports: CMPS RQD Cockpit CMPS 12M Forecast CMPS Earnings & Move CMPS Dividends & DRIP CMPS Insiders & 13F CMPS Whale Options CMPS Profit Sankey CMPS News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CMPS — COMPASS Pathways Plc American Depository Shares: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

COMPASS Pathways Plc American Depository Shares (CMPS) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $8.41 (-27.31% 1D, market capitalization $1.60B).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -9.31%.
Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

COMPASS Pathways Plc American Depository Shares is listed on NASDAQ under the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The financials report revenue of — for each reported period, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), COMPASS Pathways Plc American Depository Shares (CMPS) reported $501.3M in annual revenue (up from $499.0M in FY2024, +0.5% YoY) and -$269.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($383.4M revenue, -$118.5M net income) through FY2025, CMPS scaled operating cash flow to -$157.2M and free cash flow to -$157.2M, backed by $210.3M in total assets against $14.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.31% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $4.88 – $15.87 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data.

Key Question #1: Can CMPS sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $501.3M and free cash flow of -$157.2M, how will capital allocation balance growth reinvestment against $14.1M in total debt?
Key Question #3: How sensitive is CMPS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CMPS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for COMPASS Pathways Plc American Depository Shares (CMPS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CMPS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 22h ago

CMPS, HELP Stocks On Track For Worst Day In Months On Competitive FDA Psychedelic Race Fears

According to a report from Psychedelic Alpha, Usona has finished submitting its application for psilocybin in major depressive disorder, making it the second psychedelic under review by the agency at present.

Read Full Source ↗

🟢 CATALYST Yahoo • 1d ago

New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers

LONDON & JERSEY CITY, N.J., November 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depr

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 1d ago

1 Reason Compass Pathways Is Worth a Second Look This Month

An accelerated FDA review could benefit Compass Pathways.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Compass Pathways Issues New Report Summarizing Findings From National Survey Of People Living With TRD And Caregivers On The Burden Of Prolonged Depressive Episodes Without Meaningful Relief

The survey findings demonstrate the impact of TRD across various aspects of everyday life, with many patients reporting years spent cycling through treatments without significant improvement while the condition takes a

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 5d ago

'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana' - Marijuana Moment

https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/

Read Full Source ↗

🔴 RISK WATCH Yahoo • 5d ago

COMPASS Pathways (CMPS) Could Be 50% Below Fair Value After NEI Congress Focus

COMPASS Pathways (CMPS) drew fresh attention after confirming a prominent role at the 2026 NEI Fall Congress, highlighting its COMP360 psilocybin program and an educational initiative focused on treatment-resistant depre

Read Full Source ↗

🔴 RISK WATCH Yahoo • 6d ago

Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress

LONDON & JERSEY CITY, N.J., October 28, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participa

Read Full Source ↗

🟡 MARKET WIRE SeekingAlpha • 6d ago

Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

Compass Pathways is initially targeting the TRD market, which is large and underserved. Find out why CMPS stock is a Buy.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CMPS Bull vs. Bear Conversation Board — What's Your Call at $8.41?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CMPS 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $14.00 (+21.0%)

📌 Pinned Debate

Reported cash of $149.6M and debt of $14.1M in FY 2025 indicate a balance sheet with more cash than debt, supported by a Debt/Equity of

Reported cash of $149.6M and debt of $14.1M in FY 2025 indicate a balance sheet with more cash than debt, supported by a Debt/Equity of 0.5.. When you look under the hood at CMPS, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (9/20) has been quietly accumulating below $15.87. My 12M target is $14.00.

CapAlloc_Nerd 🐂 BULL

@MidwestValue Agree on the RQD 40/100 quality, though with 1.0 beta I'm scaling in with half-size at $11.57 and keeping dry powder in case we test $10.76.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $8.68 (-25.0%)

Spot @ $11.57

Net income of -$269.8M in FY 2025 against FCF of -$157.2M, a ROIC of -35%, and an FCF yield of -9.31% show sustained cash consumption w

Here is the bear case nobody on the bull side wants to address on CMPS: Net income of -$269.8M in FY 2025 against FCF of -$157.2M, a ROIC of -35%, and an FCF yield of -9.31% show sustained cash consumption with no reported revenue.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.